Short Interest in Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Decreases By 51.1%

Intellipharmaceutics International Inc. (OTCMKTS:IPCIFGet Rating) (TSE:I) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 2,300 shares, a drop of 51.1% from the March 31st total of 4,700 shares. Based on an average daily volume of 9,700 shares, the short-interest ratio is presently 0.2 days.

IPCIF stock traded up $0.00 during trading on Friday, hitting $0.13. 31,000 shares of the company traded hands, compared to its average volume of 3,556. Intellipharmaceutics International has a 1 year low of $0.08 and a 1 year high of $0.30. The company has a market cap of $4.14 million, a PE ratio of -0.45 and a beta of 1.69. The stock’s 50-day simple moving average is $0.13 and its 200 day simple moving average is $0.13.

Intellipharmaceutics International (OTCMKTS:IPCIFGet Rating) (TSE:I) last posted its earnings results on Monday, February 28th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Intellipharmaceutics International Company Profile (Get Rating)

Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.

Featured Articles

Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.